The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 18, 2022
Filed:
Sep. 27, 2020
Applicant:
Board of Regents, the University of Texas System, Austin, TX (US);
Inventors:
Jef De Brabander, Dallas, TX (US);
Daniel Rosenbaum, Dallas, TX (US);
Qiren Liang, Dallas, TX (US);
Wentian Wang, Dallas, TX (US);
Assignee:
Board of Regents, The University of Texas System, Dallas, TX (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); A61K 31/4355 (2006.01); A61K 31/506 (2006.01); A61K 31/501 (2006.01); A61K 31/422 (2006.01); A61K 31/423 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/4192 (2006.01); A61K 31/4709 (2006.01); C07D 491/107 (2006.01); C07D 235/30 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 409/06 (2006.01); C07D 413/06 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 491/107 (2013.01); A61K 31/4184 (2013.01); A61K 31/4192 (2013.01); A61K 31/422 (2013.01); A61K 31/423 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 31/4355 (2013.01); A61K 31/4439 (2013.01); A61K 31/4709 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); C07D 235/30 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 409/06 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01);
Abstract
Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.